New generation antipsychotic drugs and compliance behaviour

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Opinion in Psychiatry

• Publication date

  2008-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/YCO.0b013e3282f52851PMID 18332660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medication compliance and persistence: terminology and definitions.

  2008cited by this paper
• The case for long‐acting antipsychotic agents in the post‐CATIE era

  2007cited by this paper
• Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia.

  2007cited by this paper
• Quality Of Life In Schizophrenia On Conventional Versus Atypical Antipsychotic Medication: A Comparative Cross-Sectional Study

  2007cited by this paper
• Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics.

  2006cited by this paper
• Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.

  2006cited by this paper
• Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.

  2006cited by this paper
• Schizophrenia and suicide: systematic review of risk factors.

  2005cited by this paper
• Defining and assessing adherence to oral antipsychotics: a review of the literature.

  2005cited by this paper
• Adherence to medication.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Atypical antipsychotics and the burden of disease.

  2005cited by this paper
• Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

  2005cited by this paper
• Effectiveness of antipsychotic treatment for schizophrenia: 6‐month results of the Pan‐European Schizophrenia Outpatient Health Outcomes (SOHO) study

  2005cited by this paper
• Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.

  2005cited by this paper
• Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.

  2005cited by this paper
• Subjective well‐being under neuroleptic treatment and its relevance for compliance

  2005cited by this paper
• Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia

  2004cited by this paper
• Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.

  2004cited by this paper
• The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

  2004cited by this paper
• Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data

  2004cited by this paper
• Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

  2004cited by this paper
• Adherence to conventional and atypical antipsychotics after hospital discharge.

  2004cited by this paper
• Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.

  2004cited by this paper
• Medication adherence studies in schizophrenia.

  2004cited by this paper
• Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

  2003cited by this paper
• Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.

  2003cited by this paper
• Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.

  2003cited by this paper
• How often do patients with psychosis fail to adhere to treatment programmes? A systematic review

  2003cited by this paper
• Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications *

  2003cited by this paper
• The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

  2003cited by this paper
• Neuroleptic dysphoria: towards a new synthesis

  2003cited by this paper
• Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia.

  2002cited by this paper
• Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.

  2002cited by this paper
• A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

  2002cited by this paper
• Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission

  2002cited by this paper
• Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis

  2002cited by this paper
• Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

  2002cited by this paper
• Medication adherence of individuals with a first episode of psychosis

  2002cited by this paper
• Antipsychotic medication adherence: is there a difference between typical and atypical agents?

  2002cited by this paper
• Dropout rates in randomised antipsychotic drug trials

  2001cited by this paper
• Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain.

  2001cited by this paper
• Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

  2000cited by this paper
• Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses.

  2000cited by this paper
• The assessment of refill compliance using pharmacy records: methods, validity, and applications.

  1997cited by this paper
• Subjective response to neuroleptics in schizophrenia

  1997cited by this paper
• Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.

  1996cited by this paper
• Psychological Predictors of Insight and Compliance in Psychotic Patients

  1996cited by this paper
• A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables

  1995cited by this paper
• Rating of medication influences (ROMI) scale in schizophrenia.

  1994cited by this paper
• Subjective response to neuroleptics in schizophrenia.

  1993cited by this paper
• Use of prescription-refill records to assess patient compliance.

  1992cited by this paper
• Neuroleptics and the natural course of schizophrenia.

  1991cited by this paper
• A General Method of Compliance Assessment Using Centralized Pharmacy Records: Description and Validation

  1988cited by this paper
• Behavioral toxicity of antipsychotic drugs.

  1987cited by this paper
• Effect of clorazepate on depressed mood in anxious patients.

  1987cited by this paper
• Differences in the Nature of Relapse and Subsequent Inpatient Course between Medication‐Compliant and Noncompliant Schizophrenic Patients

  1984cited by this paper
• A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

  1983cited by this paper
• Compliance with Therapeutic Regimens

  1978cited by this paper

• The risk factors and predictive modeling of mortality in patients with mental disorders combined with severe pneumonia

  2024cites this paper
• CARIPRAZINE IN OFFENDER PATIENT WITH ACUTE PSYCHOSIS and aggressive behavior: Case REPORT

  2022cites this paper
• Metacognitive Training Modulates Default-Mode Network Homogeneity During 8-Week Olanzapine Treatment in Patients With Schizophrenia

  2020cites this paper
• Stigmatization experiences of Turkish parents of patients hospitalized in child and adolescent psychiatric clinics

  2019cites this paper
• Moderators of Symptomatic Outcome in Metacognitive Training for Psychosis (MCT). Who Benefits and Who Does Not?

  2018cites this paper
• A narrative meta-synthesis of how people with schizophrenia experience facilitators and barriers in using antipsychotic medication: Implications for healthcare professionals.

  2018cites this paper
• Antipsychotic drug use and pneumonia: Systematic review and meta-analysis

  2018cites this paper
• Risk Factors Associated With Readmissions of Hospitalized Mentally Ill Patients

  2017cites this paper
• Evaluation of treatment adherence in outpatients with schizophrenia

  2017cites this paper
• Metakognitives Training bei Psychose und Depression

  2016cites this paper
• Cognition, metacognition and the patient perspective : new ways to evaluate and rehabilitate schizophrenia patients in forensic psychiatric care

  2016cites this paper
• A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders.

  2015cites this paper
• Evaluating subjective domains of antipsychotic‐induced adverse effects using heart rate variability

  2015cites this paper
• Factors associated with adherence over time to antipsychotic drug treatment

  2015cites this paper
• Physical Activity and Quality of Life of Outpatients with Schizophrenia.

  2015cites this paper
• A Pilot Study of Group Administered Metacognitive Training (MCT) for Schizophrenia Patients in a High-Security Forensic Setting: Subjective Training Success and Health-Related Quality of Life

  2015cites this paper
• Individualisiertes Metakognitives Therapieprogramm für Menschen mit Psychose (MKT+)

  2015cites this paper
• Medication and participation

  2014cites this paper
• Dissociation, victimisation, and their associations with voice hearing in young adults experiencing first-episode psychosis

  2014cites this paper
• Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications

  2014cites this paper
• Development of a Patient-Centered Antipsychotic Medication Adherence Intervention

  2014cites this paper
• Metacognitive group training for forensic and dangerous non-forensic patients with schizophrenia: a randomised controlled feasibility trial.

  2014cites this paper
• Les rechutes dans la schizophrénie ; comment prévenir?

  2014cites this paper
• Experiencing antipsychotic discontinuation: results from a survey of Australian consumers.

  2014cites this paper
• A review of the adverse side effects associated with antipsychotics as related to their efficacy.

  2014cites this paper
• Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia

  2014cites this paper
• Acute and Subchronic Toxic Effects of Thioridazine versus Pimozide on Liver, Kidney and Heart of Adult Male Albino Rats: Biochemical and Histological Study

  2013influential citation
• Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents

  2013cites this paper
• Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?

  2013cites this paper
• Tolerability, Safety and Effectiveness of Paliperidone ER in Patients with Schizophrenia : A 24-Week Interim Analysis of the 48-Week Open-Label, Prospective, Switch Study

  2013cites this paper
• Dissociation, trauma, and the role of lived experience: toward a new conceptualization of voice hearing.

  2012cites this paper
• The Prevalence and Associated Factors of Psychiatric Early Readmission in a Teaching Hospital, Malaysia

  2012cites this paper
• Comparison of first and second generation antipsychotics : An update

  2012cites this paper
• Long-term safety of ziprasidone in schizophrenic patients: an open trial.

  2012cites this paper
• Exploration of the associations between neurocognitive function and neuroleptics side effects.

  2012cites this paper
• Further evidence for the efficacy of a metacognitive group training in schizophrenia.

  2011cites this paper
• Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms

  2011cites this paper
• A STUDY TO ASSESS THE ATTITUDE ON RISK FACTORS ASSOCIATED WITH COMPLIANCE AND NONCOMPLIANCE OF NEUROLEPTIC TREATMENT AMONG PATIENTS WITH SCHIZOPHRENIA

  2011influential citation
• First episode psychosis and the trail to secondary care: help-seeking and health-system delays

  2010cites this paper
• Further evidence for the effectiveness of a metacognitive group training in schizophrenia

  2010cites this paper
• The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia

  2010cites this paper
• Patients' perception of family involvement and its relationship to medication adherence for persons with schizophrenia and schizoaffective disorders

  2010cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Progress in Defining Optimal Treatment Outcome in Schizophrenia

  2010cites this paper
• Compliance-Aufbau im Fokus der Schizophreniebehandlung

  2010cites this paper
• Progress in Defining Optimal Treatment Outcome in Schizophrenia

  2010cites this paper
• Observance médicamenteuse et rechutes dans la schizophrénie : des neuroleptiques classiques aux APAP

  2009cites this paper
• Attitude towards adherence in patients with schizophrenia at discharge.

  2009influential citation
• Medical compliance and relapses in schizophrenia: From classical neuroleptics to APAP

  2009cites this paper
• Cure or Curse? Ambivalent Attitudes Towards Neuroleptic Medication in Schizophrenia and Non-Schizophrenia Patients

  2009cites this paper
• Decision making under uncertainty and mood induction: further evidence for liberal acceptance in schizophrenia

  2009cites this paper
• Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness

  2009cites this paper
• [Mental health services research: trends in psychiatric inpatient care from 1996 up to 2006].

  2008cites this paper
• Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.

  2008cites this paper
• Current awareness in human psychopharmacology.

  2008cites this paper
• Comparison of first and second generation antipsychotics: An update.

  2008cites this paper
• Versorgungsepidemiologie: Entwicklung in der stationär-psychiatrischen Versorgung 1996–2006

  2008cites this paper
• Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

  2008cites this paper